For the future of metabolic therapeutics, survodutide's Phase 2 data are encouraging, particularly for MASH where the glucagon mechanism provides a uniquely differentiated approach
Creation of Super HGF: When HGF is treated with lipoic acid trisulfide (LASSS) at an 1:8000 molar ratio, its binding affinity for c-met increases more than two-fold compared to unnitrated, native HGF while remaining highly resistant to nitration
Addressing these holistically improves the likelihood of success with GLP-1 therapy
Any references to tissue, vascular, or gastrointestinal models are provided only for research context and do not imply therapeutic or clinical use
At AgelessRx, we have taken the supplemental B12 injection and optimized it with methionine, inositol, and choline (hence the acronym MIC)